Vivos (RDGL) Shareholder's Equity Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Vivos | - | - | -3,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 5.00% |
| Jun 30, 2025 | 44.23% |
| Mar 31, 2025 | 37.63% |
| Dec 31, 2024 | 13.53% |
| Sep 30, 2024 | -5.67% |
| Jun 30, 2024 | -0.46% |
| Mar 31, 2024 | -10.63% |
| Dec 31, 2023 | 249.29% |
| Sep 30, 2023 | 54.34% |
| Jun 30, 2023 | 60.53% |
| Mar 31, 2023 | 46.27% |
| Dec 31, 2022 | 46.16% |
| Sep 30, 2022 | 52.98% |
| Jun 30, 2022 | 39.68% |
| Mar 31, 2022 | 46.88% |
| Dec 31, 2021 | 52.66% |
| Sep 30, 2021 | 26.85% |
| Jun 30, 2021 | 29.11% |
| Mar 31, 2021 | 33.14% |
| Dec 31, 2020 | 26.15% |
| Sep 30, 2020 | 37.38% |
| Jun 30, 2020 | 62.72% |
| Mar 31, 2020 | 56.26% |
| Dec 31, 2019 | 21.17% |
| Sep 30, 2019 | 62.12% |
| Jun 30, 2019 | 62.20% |
| Mar 31, 2019 | 62.40% |
| Dec 31, 2018 | 59.64% |
| Sep 30, 2018 | -58.14% |
| Jun 30, 2018 | 11.85% |
| Mar 31, 2018 | 37.83% |
| Dec 31, 2017 | 40.43% |
| Sep 30, 2017 | 27.86% |
| Jun 30, 2017 | -16.11% |
| Mar 31, 2017 | -16.99% |
| Dec 31, 2016 | 30.42% |
| Sep 30, 2016 | -37.26% |
| Jun 30, 2016 | -41.39% |
| Mar 31, 2016 | -33.46% |
| Dec 31, 2015 | -13.31% |
| Sep 30, 2015 | -14.27% |
| Jun 30, 2015 | -35.97% |
| Mar 31, 2015 | -57.02% |
| Dec 31, 2014 | -60.95% |
| Sep 30, 2014 | -31.06% |
| Jun 30, 2014 | -35.27% |
| Dec 31, 2013 | -44.61% |